Try our Advanced Search for more refined results

Expert Analysis

What's Next In The Myriad Genetics Case?

Law360, New York ( May 9, 2012, 1:01 PM EDT) -- On March 26, the U. S. Supreme Court remanded the Myriad Genetics Inc. gene patenting case to the Federal Circuit for reconsideration in light of the Supreme Court's unanimous decision in Mayo Collaborative Services v. Prometheus Laboratories, in which the court held that two patents on a method to titrate thiopurine drugs are invalid insofar as they cover unpatentable subject matter. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Law360 Reveals Titans Of The Plaintiffs Bar

This past year, a handful of attorneys secured billions of dollars in settlements and judgments for both classes and individual plaintiffs against massive companies and organizations like Facebook, Dell, the National Association of Realtors, Johnson & Johnson, UFC and Credit Suisse, earning them recognition as Law360's Titans of the Plaintiffs Bar for 2025.